Introduction {#s1}
============

Neonatal hyperbilirubinemia, or jaundice, is a common condition of the newborn, which may cause injury to neurons and glial cells, like microglia, due to increased levels of unconjugated bilirubin (UCB) ([@B12]). Neurological damage is produced by a small fraction of UCB that is not bound to albumin (free bilirubin, Bf) and cross the blood-brain barrier ([@B107]). However, the molecular mechanisms of bilirubin-induced neurological dysfunction (BIND) and the determinants of cellular vulnerability and reversibility are still only partially clarified, namely those associated with microglia activation and dysfunction. The susceptibility of neonates to BIND is also far from being understood. In our previous studies we showed that immature neurons and astrocytes are more vulnerable than older ones, and that young astrocytes produce a larger amount of inflammatory cytokines ([@B37]; [@B38]). The effects produced are related with the nervous cell type and the intrinsic signaling pathways involved. For instance, neurons revealed to be highly vulnerable to UCB-induced cell death, while glial cells are more involved in glutamate release and neuroinflammatory-associated alterations ([@B12]).

Studies on microglia dysfunction and response to elevated concentrations of UCB and Bf, aside ours, are practically non-existent. We were the first to demonstrate that UCB activates and damages microglial cells ([@B43]; [@B91]). UCB caused the switch from the ramified morphology into an amoeboid shape, first inducing phagocytosis and later on the release of inflammatory cytokines and glutamate that culminated in cell death by apoptosis and necrosis. Last evidences demonstrated that neuroinflammation is a key factor of BIND and neuro-behavioral abnormalities in a mouse model of severe neonatal hyperbilirubinemia ([@B108]), and that exosomes from the cerebrospinal fluid of full-term newborns with acute bilirubin encephalopathy contain immune-inflammatory associated proteins ([@B97]).

Microglia are the main neuroimmune cells that provide neuroprotection by constantly surveying and sensing changes within the brain, by clearing dying neurons and pathogens, and by exerting immunoregulation. To fulfill these complex and multivariate tasks, microglia adopt distinct phenotypes ([@B50]). Their functions are very important during the neurodevelopment period, by participating in neurogenesis and synaptic pruning programs ([@B28]). It is nowadays accepted that microglia activation occurs in a continuum way and involves changes in gene expression and metabolism, cellular morphology, motility, migration, phagocytosis, proliferation, and ultimately death, as well as variations in cell-derived secretome ([@B79]).

Recently, it was shown that the secretome from phagocytic microglia restricts neurogenesis, modulating the balance between proliferation and survival, at least in the neurogenic niche ([@B31]). In addition, it was shown that the secretome from the anti-inflammatory microglia increase the survival and migration of neural stem cells, while restrains astrocyte differentiation, as compared with the pro-inflammatory phenotype ([@B66]). Upon activation, microglia release a variety of toxic and proinflammatory mediators, such as reactive oxygen and nitrogen species, cytokines, alarmins and inflammatory-associated microRNAs (inflamma-miRs) ([@B11]; [@B94]; [@B47]; [@B13]). In such conditions, microglia can present multiple activation phenotypes that may co-exist due to their plasticity ([@B95]). In the steady-state, the surveilling microglia express the CX3C chemokine receptor 1 (CX3CR1) for the neuronal fractalkine (CX3CL1) ([@B89]), an axis with important role in the communication between neurons and microglia, as well as in the modulation of neuroinflammation ([@B27]; [@B98]; [@B5]). CX3CR1 relevance was also demonstrated in the synaptic refinement and transmission in the developing hippocampus ([@B71]). Microglia activation also results from the stimulus of damaged-associated molecular pattern (DAMP) alarmins that are released from dying cells and stimulate the innate immune system ([@B46]). One of the most important is the high mobility group box 1 (HMGB1) that, similarly to pro-inflammatory cytokines, interacts with Toll-like receptors (TLRs), among others, inducing the transcription of inflammatory mediators. HMGB1 by activating the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome ([@B24]) promotes the maturation and release of interleukin (IL)-1β by the activation of caspase-1 ([@B109]).

Inflamma-miRs have a critical function in inducing microglia polarization and once in the microglia secretome have a paracrine impact on the modulation of other cell types ([@B3]; [@B40]; [@B105]; [@B13]). From the several inflamma-miRs, miR-155 and miR-125b usually associate with a pro-inflammatory phenotype, miR-124 with immunoregulation ([@B77]; [@B49]), and miR-146a and miR-21 with anti-inflammatory effects and cellular senescence ([@B15]). Expression of inflamma-miRs by microglia were found to be age-dependent ([@B17]; [@B53]). We showed that microglia isolated from the brain cortex of 2 day-old mice and kept for short- and long-term cultures, switch from an activated/reactive to senescent-like phenotypes ([@B18]). Increased BIND in the neonatal period may relate with a specific predisposition of the young microglia to bilirubin injury, a topic that was never investigated.

Bf neurotoxicity has been related with concentrations near or modestly above its aqueous solubility of 70 nM ([@B67]). Actually, Bf levels below 70 nM were shown to protect neuronal cells from oxidative damage ([@B6]; [@B87]). However, we reported that concentrations of 100 and even 10 nM Bf may cause oxidative stress and injury to neocortical synaptosomes after 4 h of incubation ([@B14]). Recently, 24 h and 48 h treatment with 70 nM and 140 nM Bf compromised the cell viability of SH-SY5Y human cells and the highest concentration caused oxidative stress and DNA damage ([@B81]). Such protective and neurotoxic distinct effects may associate to different cell types and culture models used by the researchers.

Having all the above comments in mind, in this study we evaluated how young and long-maturated mouse cortical microglia are activated/injured by Bf concentrations of 50 nM (below the limit of 70 nM) and 100 nM (slightly above the aqueous solubility), after 24 h culture. For that, we used our established primary microglial cell culture model to obtain cells with 2 and 16 days *in vitro* (DIV) ([@B18]; [@B19]). We examined microglia morphologies and markers of oxidative stress, as well as the expression of the glutamate transporter GLT-1, HMGB1, CX3CR1, and inflammatory-associated mediators, including inflamma-miRs, in each differently aged microglia treated with 50 and 100 mM Bf, to better understand the role of microglia in the increased susceptibilities of preterm and term neonates to UCB neurotoxicity.

Our data show that young (2DIV) microglia are more likely activated, with increased number of amoeboid cells and HMGB1 positive cells than long-maturated (16DIV) ones. Overexpression of GLT-1, inducible nitric oxide synthase (iNOS), inflammatory cytokines, major histocompatibility complex II (MHCII), arginase 1, and all inflamma-miRs, except miR-124, was the result of both Bf concentrations in immature cells. On the other hand, the long-maturated microglia were more irresponsive to UCB-immunostimulation. These cells just showed increased CX3CR1, depressed inflamma-miRs and upregulation of arginase 1 and IL-1β, thus revealing a restrained inflammatory phenotype upon interaction with Bf. Such understanding may be important to define therapeutic interventions to recover microglia neuroprotection in jaundiced neonates presenting an increased risk of UCB encephalopathy.

Materials and Methods {#s2}
=====================

Animals {#s2_1}
-------

This study was performed in accordance with the European Community guidelines (Directives 86/609/EU and 2010/63/EU, Recommendation 2007/526/CE, European Convention for the Protection of Vertebrate Animals used for Experimental or Other Scientific Purposes ETS 123/Appendix A) and Portuguese Laws on Animal Care (Decreto-Lei 129/92, Portaria 1005/92, Portaria 466/95, Decreto-Lei 197/96, Portaria 1131/97). All the protocols used in this study were approved by the Portuguese National Authority (General Direction of Veterinary). Every effort was made to minimize the number of animals used and their suffering.

Primary Culture of Microglia {#s2_2}
----------------------------

Mixed glial cultures were prepared from 1- to 2-day-old CD1 mice as usual in our lab ([@B18]). Briefly, cells (4 × 10^5^ cells/cm^2^) were plated in culture medium \[DMEM-Ham's F-12 medium supplemented with 2 mM [L]{.smallcaps}-glutamine, 1 mM sodium pyruvate, non-essential amino acids, 10% fetal bovine serum (FBS), and 1% antibiotic-antimycotic\] and maintained at 37°C in a humidified atmosphere of 5% CO~2~. After 21 days in mixed culture, microglia were isolated by mild trypsinization according to the method of [@B85]. This method resulted in the detachment of an upper layer of cells containing astrocytes, whereas microglia remained attached to the bottom of the well. The medium containing detached cells was removed and the initial mixed glial-conditioned medium was added. Culture medium was replaced every 4 days and attached microglia were maintained in culture until 2 or 16DIV, in order to have young and long-maturated cells, respectively ([@B18]). Purity of microglia was nearly 100% in 2DIV cells and 98% in 16DIV cells, in which astrocytes accounted for the 2% contamination when assessed by immunocytochemical staining with a primary antibody against glial fibrillary acidic protein (GFAP). Contamination by neurons was null after staining with microtubule-associated protein 2 (MAP-2). Characterization of the 2DIV and 16DIV microglia was previously described for nuclear factor kappa B (NF-κB) activation, migration ability, phagocytic capacity, together with reactive and cell senescence markers ([@B18]).

Cell Treatment {#s2_3}
--------------

Microglia with 2DIV and 16DIV were incubated during 24 h, at 37°C, in the absence (control) or in the presence of 50 and 100 nM Bf which mimic the concentrations found in moderate and severe neonatal jaundiced conditions, respectively. Such concentrations were selected considering that the aqueous saturation limit is 70 nM and that toxicity usually occurs at Bf levels near or modestly above the aqueous solubility of bilirubin ([@B67]). Stock Bf solutions were extemporarily prepared in 0.1 N NaOH solution, immediately before incubation and under light protection to prevent photo-degradation. Value of pH was adjusted to 7.4 by adding 0.1 N HCl. UCB was obtained from Sigma and purified as usual in our lab ([@B103]).

Immunocytochemistry {#s2_4}
-------------------

We assessed microglia activation by evaluating cell morphology with Iba1 and CD11b intensity/area by immunostaining. After incubation, cells were fixed for 20 min with 4% (w/v) paraformaldehyde and incubated with primary antibodies raised against Iba1 (rabbit, 1:150, Wako) or Cd11b (rat, 1:100, Biolegend), followed by species-specific secondary antibodies. For HMGB1, we used the primary antibody against HMGB1 (mouse, 1:100, Biolegend) followed by species-specific secondary antibody. In this case, we counted the percentage of HMGB1-positive cells above a certain threshold, considering the same background and time of exposure when acquiring the image. We also evaluated glutamate transporter GLT-1 expression by immunocytochemistry. Here, we used the primary antibody raised against GLT-1 (rabbit, 1:180, Abcam) followed by species-specific secondary antibody. Data were expressed as fold change relatively to aged-matched non-treated cells (control).

In all cases, cell nuclei were stained with Hoechst 33258 dye. Fluorescence was visualized using a fluorescence microscope (model AxioScope.A1) coupled with AxioCam HR (Zeiss). Ten random fields were acquired per sample. Image analysis and processing of the fluorescent-labelled cells were done using ImageJ software, and individual microglia manually traced with this software ([@B29]).

Quantification of Nitrite Levels {#s2_5}
--------------------------------

Levels of nitric oxide (NO) were estimated by measuring the concentration of nitrites (NO~2-~), a product of NO metabolism, in the supernatants of microglial cells ([@B103]). Extracellular media, free from cellular debris, was mixed with Griess reagent \[1% (w/v) sulfanilamide in 5% H~3~PO~4~ and 0.1% (w/v) N-1 naphtylethylenediamine, from Sigma-Aldrich, in a proportion of 1:1 (v/v)\] in 96-well tissue culture plates for 10 min in the dark, at room temperature. The absorbance was red at 540 nm using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA) and a calibration curve used in each assay. Results were expressed as fold change relatively to aged-matched non-treated cells (control).

Mitochondria Fluorescence Intensity {#s2_6}
-----------------------------------

The mitochondrial-related oxidative activity was detected by Mitotracker^®^ Red CMXRo (Invitrogen), a soluble dye that permeates live cells in the not-fluorescent form and, once inside the cells, is oxidized and converted into the fluorescent form, thus staining active mitochondria ([@B7]). After incubation, cells were incubated with 100 nM MitoTracker dye, under light protection, for 30 min at room temperature. Cells were then fixed for 20 min with paraformaldehyde 4% in PBS. Cell nuclei were stained with Hoechst 33258 dye (1:1000) and the relative fluorescence was visualized by fluorescence microscope. Ten fields were captured randomly and analysed by using the ImageJ software. The number of nuclei was counted and the average MitoTracker intensity per cell calculated. Results were then expressed as fold change relatively to aged-matched non-treated cells (control).

Quantitative Real-Time PCR {#s2_7}
--------------------------

Quantitative Real-Time (qRT)-PCR was performed as usual in our lab ([@B105]). Briefly, total RNA was extracted from microglia using TRIzol^®^ (LifeTechnologies), according to manufacturer's instructions. Total RNA was quantified using Nanodrop ND-100 Spectrophotometer (NanoDrop Technologies) and conversion to cDNA was performed with GRS cDNA Synthesis Master Mix (GRiSP, Porto, Portugal). qRT-PCR was performed on a QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems) using an Xpert Fast Sybr Blue (GRiSP). qRT-PCR was accomplished under optimized conditions: 50°C for 2 min followed by 95°C for 2 min and finally 50 cycles at 95°C for 5 s and 62°C for 30 s. In order to verify the specificity of the amplification, a melt-curve analysis was performed, immediately after the amplification protocol. Non-specific products of PCR were not found in any case. Results were normalized to β-actin and expressed as fold change. The sequences used for primers are indicated in the [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. For miRNA analysis, conversion of cDNA was achieved with the universal cDNA Synthesis Kit (\#203301, Exiqon), following manufacturer's recommendations and as usual in our lab ([@B29]). The Power SYBR^®^ Green PCR Master Mix (Applied Biosystems) was used in combination with predesigned primers (Exiqon), indicated in the [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}, using SNORD110 as the reference gene. The reaction conditions consisted of polymerase activation/denaturation and well-factor determination at 95°C for 10 min, followed by 50 amplification cycles at 95°C for 10 s and 60°C for 1 min (ramp-rate 1.6°/s). Relative mRNA and miRNA concentrations were calculated using the ΔΔCT equation. All samples were measured in duplicate. Results were expressed as fold change relatively to aged-matched non-treated cells (control).

Determination of Cell Death {#s2_8}
---------------------------

The rates of cell viability were obtained by Guava Nexin flow cytometry (Guava easyCyte 5HT flow cytometer) that differentiated three cell populations: viable cells (annexin V-PE and 7-AAD negative), early-apoptotic cells (annexin V-PE positive and 7-AAD negative) and late-apoptotic/necrotic cells (annexin V-PE and 7-AAD positive). In brief, after incubation with trypsin for 5 min at 37°C, the cells were collected and joined to the incubation media. Then the samples were precipitated and re-suspended in PBS (with BSA 1%). Guava Nexin^®^ Reagent was added to the samples during 20 min in darkness, following manufacturer's instructions and as usual in our lab ([@B42]).

Statistical Analysis {#s2_9}
--------------------

Results from at least three different independent experiments, performed in duplicate, were expressed as mean ± SEM. For each time in culture (2DIV or 16DIV), comparisons between non-treated microglia (control) and Bf-treated (50 nM and 100 nM) were performed by one-way ANOVA followed by multiple comparisons Bonferroni post-hoc correction using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). P-values of 0.05 were considered statistically significant.

Results {#s3}
=======

Young Microglia Are Particularly Susceptible to Bf-Induced Activation and Sickness Response {#s3_1}
-------------------------------------------------------------------------------------------

We have previously demonstrated that cortical microglia isolated from 1- to 2-day-old mice pups, maintained 21 days in mixed culture with astrocytes, separated by mild trypsinization and cultured for only 2DIV show a reactive phenotype ([@B18]). However, such profile changed to a mature phenotype at 10DIV and to a less responsive and senescent-like microglia at 16DIV (e.g. reduced phagocytic and migration abilities, together with increased senescent-associated β-galactosidase activity and miR-146a levels). Here, we evaluated how such age-differentiated 2DIV and 16DIV microglia react to 50 nM and 100 nM Bf, considering that the first is below its aqueous saturation limit of 70 nM and the later above, with propensity to induce BIND ([@B67]). These concentrations allowed us to use Bf without the need of having albumin in the milieu, a condition that better mimics the *in vivo* conditions once albumin is not present in the brain, unless there is compromise of the blood-brain barrier. Moreover, though previously indicated to prevent UCB-induced toxicity towards neurons and astrocytes in mature and immature rat hippocampal slices ([@B30]), albumin was also reported to activate microglia and cause neurotoxicity ([@B52]), what could compromise the effects of Bf by itself.

We first assessed whether Bf was able to change microglia viability. As indicated in [**Table 1**](#T1){ref-type="table"}, though no significant alterations were produced in the number of viable cells, both Bf concentrations increased the percentage of 2DIV cells suffering early apoptosis (6 and 7% *vs.* 3% in controls) and that of 16DIV presenting late apoptosis (between 8 and 9% *vs.* 3% in controls), indicating different cell integrity compromise by Bf depending from the time in culture. It should be noted, however, that in any circumstance cell death relatively to controls surpassed the value of 10%, attesting the validity of the model to assess microglia functional differences upon Bf treatment.

###### 

Percentage of viable, early apoptotic, and late apoptotic/necrotic microglia populations before and after treatment with free bilirubin concentrations.

                  2 DIV        16 DIV                                             
  --------------- ------------ ------------- ----------- ------------ ----------- -------------
  **Control**     91.3 ± 1.5   3.2 ± 0.4     3.8 ± 0.5   90.4 ± 1.6   3.8 ± 0.4   3.2 ± 0.2
  **Bf 50 nM**    87.6 ± 1.0   6.6 ± 1.2\*   6.5 ± 1.0   87.4 ± 0.7   3.9 ± 1.0   8.3 ± 1.3\*
  **Bf 100 nM**   88.6 ± 1.2   5.6 ± 0.7\*   7.0 ± 1.2   86.5 ± 0.8   3.9 ± 0.6   8.8 ± 0.7\*

Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with free bilirubin (Bf) at 50 and 100 nM, during 24 h. After incubation, the percentage of viable, early apoptotic, and late-apoptotic/necrotic cells were determined by flow cytometry with phycoerythrin-conjugated annexin V (annexinV-PE) and 7-amino-actinomycin D (7-AAD). The three populations were distinguished as follows: viable cells (annexin V-PE and 7-AAD negative), early apoptotic cells (annexinV-PE positive and 7-AAD negative), and cells in late stages of apoptosis or necrosis (annexinV-PE and 7-AAD positive). Results are mean± SEM from at least 3 independent experiments performed in duplicate. \*p\<0.05 vs. respective control.

Microglia activation is usually associated with rounded/amoeboid shapes, while the ramified morphology relates with the surveillant state ([@B44]). Bf-stimulation of microglia morphological alterations after 24 h incubation was assessed by immunofluorescent labelling against Iba1. While the Bf-treated 16DIV cells remained ramified (almost 100%), an increased number of amoeboid cells was observed in the 2DIV microglia ([**Figure 1**](#f1){ref-type="fig"}), supporting the acquisition of a more activated/reactive stage ([@B32]). To note that the effects were similar with either 50 or 100 nM of Bf (p\<0.05). We hypothesize that such result derives from the soluble fraction interacting with the microglia plasmatic membrane, i.e., the Bf soluble species. Evaluation of CD11b immunostaining, a β-integrin marker associated with microglial activation during neurodegenerative inflammation ([@B83]), further validated the preferential activation of 2DIV cells relatively to 16DIV microglia ([**Figure 2**](#f2){ref-type="fig"}). As a proof of concept for the increased reactivity in younger microglia, we evaluated the constitutive "calming" microglial signaling marker CX3CR1. Indeed, CX3CR1 expression has been associated with a steady state/surveilling microglia and linked to the neuronal CX3CL1 signaling in the healthy brain ([@B36]). In [**Figure 3A**](#f3){ref-type="fig"}, it is evident that 100 nM Bf reduces the expression of CX3CR1 in 2DIV cells (p\<0.05), which is consistent with the activated profile previously observed in the young microglia. In contrast, CX3CR1 gene expression was induced by both Bf concentrations in 16DIV cells, thus accounting for their supportive behavior when in the presence of Bf.

![2 DIV microglia develop an amoeboid morphology upon incubation with free bilirubin (Bf), an effect not produced in the 16 DIV aged cells. Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with 50 nM and 100 nM Bf for 24 h. After incubation, morphological analysis was performed by immunocytochemistry using anti-Iba1, as indicated in methods. Representative results of one experiment are shown **(A)**. Percentage of cells with ramified and amoeboid morphologies were quantified **(B)**. Scale bar represents 40 μm. Results are mean ± SEM from at least 3 independent experiments performed in duplicate. \*p \< 0.05 *vs.* respective controls (untreated cells).](fphar-11-01012-g001){#f1}

![Expression of Cd11b increases in microglia after incubation with free bilirubin (Bf), though more notoriously in young 2DIV cells. Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with 50 nM and 100 nM Bf for 24 h. After incubation, analysis of Cd11b intensity was performed by immunocytochemistry using anti-CD11b, as indicated in methods. Representative results of one experiment are shown **(A)**. Quantification of the fluorescence was performed by determining the mean fluorescence intensity of each cell and normalized to their total area **(B)**. For that, individual cells were manually traced using ImageJ software. Scale bar represents 40 μm. Results are mean ± SEM from at least 3 independent experiments performed in duplicate. \*p \< 0.05 and \*\*p \< 0.01 *vs.* respective controls (untreated cells).](fphar-11-01012-g002){#f2}

![Activation of 2DIV microglia with free bilirubin (Bf) is associated with decreased CX3CR1 and increased HMGB1 levels, which are not observed in 16DIV cells. Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with 50 nM and 100 nM Bf for 24 h. After incubation, CX3CR1 **(A)** and HMGB1 **(B)** gene expression was evaluated by Real Time-PCR, as specified in methods. HMGB1 protein detection was performed by immunocytochemistry using anti-HMGB1, as indicated in methods. Representative results of one experiment are shown **(C)**. Percentage of HMGB1 positive cells was performed using ImageJ software and applying a threshold **(D)**. Results are fold change **(A, B)** and mean percentage ± SEM (D) *vs.* respective control (untreated cells) from at least 4 independent experiments performed in duplicate. \*p \< 0.05 and \*\*p \< 0.01 *vs.* respective controls.](fphar-11-01012-g003){#f3}

The alarmin HMGB1 can be released under pathological conditions and initiate inflammatory cascades. In our model, we observed a marked elevation of HMGB1 gene expression in the young cells exposed to Bf 50 nM and to 100 nM, while no differences were found in the long-maturated cells ([**Figure 3B**](#f3){ref-type="fig"}). Since the effects of HMGB1 are dependent on complex formation with different ligands that usually activate the innate immune system and promote inflammation ([@B88]; [@B113]), we additionally evaluated if the localization of the HMGB1 protein was cytoplasmic or nuclear, and quantified the number of HMGB1-positive cells by immunofluorescence (above a common threshold). As depicted in [**Figures 3C, D**](#f3){ref-type="fig"}, HMGB1 was found present in both nucleus and cytoplasm, with an increased number of 2DIV positive microglia upon interaction with 50 nM Bf (p\<0.05), relatively to the non-treated cells (control). In contrast, 16DIV microglia behaved as non-responders to the Bf stimulus.

To further explore the activation of 2DIV microglia by Bf, we next explored the expression of GLT-1, since it was shown to be highly expressed by activated microglia after facial nerve axotomy ([@B61]), or subsequently to LPS stimulation and tumor necrosis factor-alpha (TNF-α) increase ([@B75]). Such upregulation of GLT-1 was suggested to be a mechanism to prevent glutamate excitotoxicity ([@B58]), which contributes to neuronal damage during neuroinflammation ([@B8]). As expected, GLT-1 expression by immunocytochemistry was upregulated by both concentrations of Bf in the 2DIV microglia (p\<0.05), contrasting with no changes in the long-maturated cells ([**Figure 4**](#f4){ref-type="fig"}). These results reinforce the ability of Bf to activate the young microglia and indicate that the long-matured cells acquire resistance to the immunostimulant effects of Bf.

![Free bilirubin (Bf) upregulates GLT-1 only in young microglia. Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with 50 nM and 100 nM Bf for 24 h. After incubation, detection of GLT-1 levels was performed by immunocytochemistry using anti-GLT-1, as indicated in methods. Representative results from one experiment are shown **(A)**. Scale bar represents 40 μm. Quantification of the mean fluorescence intensity of GLT-1 in each cell was normalized to their total area **(B)**. For that, individual cells were manually traced using ImageJ software. Results are mean ± SEM fold change *vs*. respective controls (untreated cells) from at least 5 independent experiments performed in duplicate. \*p \< 0.05 *vs.* respective control.](fphar-11-01012-g004){#f4}

Elevated Levels of Bf Only Accelerate Mitochondrial-associated Nitric Oxide Stress in 2DIV Cells, Though Upregulate iNOS Gene Expression in Both Young and Aged Microglia {#s3_2}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Taking into account the activation profile induced by Bf and because oxidative stress is a central regulator of HMGB1's translocation, release, and activity in inflammation and cell death ([@B114]), we further assessed nitrosative stress-related mediators in our model. As depicted in [**Figure 5A**](#f5){ref-type="fig"}, a clear elevation of NO production was observed in 2DIV Bf-treated microglia (p\<0.05) with concentration-independent levels. In contrast, the 16DIV cells showed a reduction (p\<0.05), which was again similar for 50 nM and 100 nM Bf. Data reinforce the age-dependent response of microglia to these concentrations of Bf in terms of NO production. However, when we evaluated the mRNA gene expression of inducible nitric oxide synthase (iNOS), we verified that both 2DIV and 16DIV exhibited elevated levels when treated with Bf 100 nM (p\<0.01, [**Figure 5B**](#f5){ref-type="fig"}). Equally, increased gene expression of iNOS in the same model and independently of the microglia age in culture was obtained upon amyloid-β exposure (Aβ) ([@B19]).

![High levels of free bilirubin (Bf) upregulate iNOS gene expression in the differently aged microglia, though mitochondrial-associated NO stress only occurs in 2DIV cells. Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with 50 nM and 100 nM Bf for 24 h. After incubation, NO levels **(A)** were assessed by Griess reagent and iNOS mRNA **(B)** by Real Time-PCR. Mitochondria was stained with mitotracker red and representative results from one experiment are shown **(C)**. Fluorescence intensity values were obtained by using ImageJ software to define the integrated density **(D)**. Results are mean± SEM fold change *vs*. respective controls (untreated cells) from at least 4 independent experiments performed in duplicate \*p \< 0.05 and \*\*p \< 0.01 *vs.* respective controls.](fphar-11-01012-g005){#f5}

To assess whether the NO release resulted from an increase in microglial mitochondrial activity, we have used MitoTracker^®^ Red, a cell-permeant probe that enters in actively respiring cells, where it is oxidized and sequestered in the mitochondria, reacting with thiols of proteins/peptides and forming an aldehyde-fixable conjugate. Higher staining densities of this probe was present in 2DIV cells treated with Bf 100 nM (p\<0.05, [**Figures 5C, D**](#f5){ref-type="fig"}), while changes were absent in 16DIV cells, suggesting that only the younger cells increase mitochondrial-related NO stress upon Bf stimulation. Therefore, we may hypothesize that the elevation of iNOS by an age-independent Bf stimulation can result from other simultaneous intracellular activated signaling pathways not involving mitochondria ([@B2]).

Upregulation of Transcriptional Inflammatory Pathological Profiles Is a Specific Feature of Bf-Treated Young Microglia {#s3_3}
----------------------------------------------------------------------------------------------------------------------

Having observed that 2DIV microglia show a higher susceptibility to activation by Bf than the long-maturated cells, we next determined the differential expression of polarized-specific genes in Bf-treated cells. In our previous studies the use of genes associated with anti-inflammatory and pro-inflammatory microglia allowed the categorization of microglia polarized state subpopulations ([@B91]; [@B92]), including in the 2DIV/16DIV model here used ([@B18]; [@B19]).

As shown in [**Figure 6**](#f6){ref-type="fig"}, arginase 1 and IL-1β were equally elevated in 2DIV and 16DIV microglia after treatment with Bf (p\<0.01 and p\<0.05 in the first and p\<0.01 in 2DIV cells, p\<0.05 in 16DIV ones for the later, for both Bf concentrations). Also included in the similar transcriptional profile induced by Bf-stimulation in young and aged microglia is the decrease of the anti-inflammatory IL-10 (p\<0.05 for both Bf concentrations in the former and only for Bf 100 nM in the later). However, the young activated microglia were unique in additionally displaying upregulated transcriptional profiles of MHCII, TNF-α and IL-6 (more than 10-fold), supporting the increased proinflammatory population subtypes generated by Bf stimulation in young cells relatively to the older ones that revealed to be poor responders.

![Young microglia treated with high levels of free bilirubin (Bf) show a prevalent upregulation of transcriptional inflammatory mediators, which are marginally exhibited by 16DIV cells. Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with 50 nM and 100 nM Bf for 24 h. After incubation, mRNA expression of MHCII, Arginase 1 (Arg1), TNF-α, IL-1β, IL-6, and IL-10 was determined by Real Time-PCR in 2 DIV **(A)** and 16 DIV **(B)** cells. Results are mean± SEM fold change *vs*. respective controls (untreated cells) from at least 5 independent experiments performed in duplicate. \*p \< 0.05 and \*\*p \< 0.01 *vs.* respective controls.](fphar-11-01012-g006){#f6}

Though there is still an incomplete clarification of the role of miRNAs in microglia, either in health or in neuropathological conditions, the dysregulation of certain miRNAs, such as inflamma-miRs, are known to contribute to abnormal cell polarization, hyper-activation and persistent neuroinflammation ([@B40]; [@B47]). Validating the Bf-induced signature of the common inflammatory mediators previously found in 2DIV microglia, almost all the assessed inflamma-miRs were overexpressed in young cells, but downregulated in the long-cultured microglia, independently of the concentrations ([**Figure 7**](#f7){ref-type="fig"}). Taking into account the 3 miRNAs more involved in microglia inflammatory response, miR-155, miR-146a, and miR-124 ([@B96]), the first two were upregulated in 2DIV microglia by Bf, while were depressed in the 16DIV microglia, thus reinforcing the irresponsive character of the aged microglia towards Bf. Relatively to the anti-inflammatory miR-124, it was decreased in both, this time reflecting a common deficient microglia reparative action upon Bf, independently of the age in culture ([**Figure 7**](#f7){ref-type="fig"}). Now, if we consider the additional increase of miR-125b and miR-21 in the 2DIV Bf-treated microglia, these results additionally suggest that both anti-inflammatory and pro-inflammatory subtypes are produced by Bf originating mixed activated populations.

![Young microglia treated with high levels of free bilirubin (Bf) show upregulation of miRNAs that mediate neuroinflammation, an effect inversely sensed by the long-maturated cells. Microglial cells were treated at 2 and 16 days-in-vitro (DIV) with 50 nM and 100 nM Bf for 24 h. After incubation, expression of miR-155/-125b/-21/-146a/124 was determined by Real Time-PCR, either in 2 DIV **(A)** or 16 DIV **(B)** cells. Results are mean± SEM fold change *vs*. respective controls (untreated cells) from at least 5 independent experiments performed in duplicate. \*p \< 0.05 and \*\*p \< 0.01 and *vs.* respective controls.](fphar-11-01012-g007){#f7}

Overall, our results point that the susceptibility of young/activated microglia to Bf-induced inflammatory response may associate to the damaging effects of hyperbilirubinemia during the neurodevelopment period and may be implicated in poorer outcomes of the prematurely born neonates, highlighting the need of immunoregulatory strategies against BIND in the sickest infants.

Discussion {#s4}
==========

In a previous work, we developed an experimental method to naturally age microglia after isolation from the cortex of neonatal mice brains ([@B18]). We showed that these cells presented markers of a reactive phenotype early in culture (2DIV) and that such profile changed along time (until 16DIV) to a less responsive microglia showing senescence biomarkers and miRNAs of a deactivated/irresponsive subtype. More recently, we demonstrated that 16DIV microglia are poorer responders to amyloid-beta (Aβ) peptide stimulation, when compared to 2DIV cells, showing reduced phagocytosis, migration ability and inflamma-miR expression ([@B19]). UCB/Bf have been associated to either anti-oxidant or neurotoxic properties in nerve cells depending on their concentrations ([@B33]; [@B34]). Moreover, a wide spectrum of neuropathological findings by Bf in neonates and in experimental models have been documented ([@B112]; [@B20]; [@B68]; [@B12]; [@B21]). Age-dependent pattern of susceptibilities to BIND have been successively also demonstrated in neural cells and mice models ([@B37]; [@B38]; [@B10]). However, only few studies addressed the harmful effects of UCB/Bf in microglia function ([@B43]; [@B91]), and none investigated whether differences in young and adult/aged microglia to Bf insults may account to the increased vulnerabilities of neonates to hyperbilirubinemia. Thus, the present work was designed to evaluate the response of young *vs.* aged microglia to Bf stimulus at concentrations mimicking moderate to high increased associated risks. The data presented here support the concept that Bf induces differential transcriptional profiles in short- and long-cultured microglia (young/aged cells) with a predominant activation and inflammatory profile manifested by the young microglia.

Modification of microglial morphology is one of the hallmarks of cell activation and polarization ([@B23]; [@B63]). For that reason, we started by assessing the morphological features of microglial cells upon Bf incubation. Our first results based on Iba1 staining indicate that microglia are preferentially activated by Bf at 2DIV, as compared with 16DIV cultures, with an increased number of cells with an amoeboid shape, as well as increased CD11b stainning. Similar profiles were obtained in microglia isolated from Wistar rats at 1- to 2-day-old and treated with elevated concentrations of UCB ([@B91]) and in the Gunn rat, a model of bilirubin encephalopathy ([@B60]). Rather than the originally-perceived all or-none response, it is now accepted that microglia are plastic cells adopting diverse phenotypes when activated ([@B62]). Considering that the ramified morphology is characteristic of surveillant microglia, while the amoeboid shape predominates in the activated-state ([@B44]), our results show an increased number of activated cells by Bf among the young cultured microglia population. Increased susceptibility of young/immature astrocytes and neuronal cells to UCB, as compared to maturated cells, was previously evidenced ([@B37]; [@B38]). Early apoptosis was mainly produced in young cells while late apoptosis/necrosis was observed in the aged cells, suggesting a different balance of negative and positive factors in age-associated cell dysfunction ([@B101]). Such findings strongly suggest that Bf-induced toxicity develops near (50 nM) or slight above (100 nM) the aqueous saturation limit of 70 nM, a range in which UCB monomers, oligomers, and metastable small colloids are likely present ([@B67]). When we further characterized the expression of cell markers associated to microglia differential polarized states, we observed a decrease of the cell "calming" signal CX3CR1 in the 2DIV microglia, probably accounting for their preferential activated profile upon Bf interaction. CX3CR1-deficient activated microglia were previously associated to increased phagocytosis ([@B59]), deficient synaptic integration and emotional behavioral alterations in mice ([@B9]), as well as to impaired cognitive function *via* increased IL-1β ([@B82]). Excessive microglia phagocytosis of synapses and neurons is implicated in diverse pathological processes ([@B106]). Once CX3CL1-CX3CR1 axis is an important pathway to promote synaptic plasticity processes ([@B89]), the increased levels of microglia CX3CR1 only in 16DIV after Bf exposure may reflect an adaptive cell response to promote neuronal-microglial communication. Nevertheless, elevated levels of CX3CR1 and BDNF in microglia were also associated with autism spectrum disorders ([@B35]). In fact, both protective and detrimental effects have been reported for CX3CR1 deletion ([@B48]) and the consequences of low and high CX3CR1 expression in 2DIV and 16DIV Bf-treated microglia should be later explored in co-cultures of neurons and microglia.

The microglial "alarming" signal HMGB1 is known to function as a proinflammatory cytokine and to cause neurodegeneration, being suggested as a therapeutic target ([@B73]). Actually, HMGB1 released from inflamed microglia was shown to bind to Mac1 (macrophage antigen complex 1) and activate the NF-κB pathway, as well as the NADPH oxidase, thus stimulating the production of multiple inflammatory and neurotoxic factors ([@B41]). Considering the association of HMGB1 with such neuroinflammatory events we anticipated its upregulation mainly in the young Bf-treated microglia. Indeed, we observed increased transcriptional profile, higher levels of cytoplasmatic HMGB1 and enhanced HMGB1-positive cells in 2DIV Bf-treated microglia, but no changes in aged ones. Such profile agrees with previous studies showing that HMGB1 and the downstream cellular inflammatory response are enhanced in young, relatively to adult or old mice ([@B78]; [@B111]). Due to its role in sustaining inflammation and causing chronic neurodegeneration ([@B64]), as well as in mediating the process of fetal and neonatal tissue injury ([@B16]), HMGB1 targeting may reveal a promising therapeutic strategy to prevent BIND and outcomes beyond the inflammatory response in neonates.

During the neuroinflammatory process, microglia release glutamate that causes excitotoxicity and exacerbates neurotoxicity ([@B8]), but also participate in its uptake by expressing different types of glutamate transporters ([@B57]), as is the case of GLT-1 that is upregulated in activated microglia ([@B61]; [@B75]). Release of substantial levels of glutamate from microglia in response to bilirubin was previously demonstrated ([@B43]; [@B91]). Here, GLT-1 increase only occurred in the young/immature Bf-treated microglia suggesting a protective intervention against the Bf stimulus on glutamate release ([@B39]; [@B43]). Actually, UCB-induced release of glutamate is higher in young than in old nerve cells ([@B38]) and may relate with the increased levels of HMGB1, which are known to stimulate the glutamate release in mice synaptosomes and astrocytic gliosomes ([@B74]).

In earlier studies we have demonstrated that UCB induces nNOS expression and NO production in immature rat neurons cultured for 3DIV ([@B104]), while also causes NO production by activated microglia in organotypic hippocampal slices from 7- to 10-day-old Wistar rats ([@B93]).

In this study, we showed that Bf at 100 nM upregulates iNOS gene expression in both young and aged cultured cortical mouse microglia. Overexpression of iNOS was found in amoeboid microglia in developing retina, while downregulated levels were observed in ramified microglia ([@B90]). Several signalling cascades determine the expression of iNOS in glial cells, whose elevated levels are observed during neuroinflammation in neurodegenerative disorders ([@B84]). Our data show that Bf produces a wide variety of proinflammatory and degenerative stimuli mainly in the young microglia and, therefore, iNOS upregulation may result from Bf direct immunostimulation. On the other hand, iNOS increase in 16DIV cells can be related with an enhanced IL-1β-induced iNOS due to microglia alterations by aging ([@B65]), as the enhanced late apoptosis/necrosis suggest in these cells. However, just the 2DIV Bf-treated cells led to NO generation by either one of the tested concentrations, since the 16DIV microglia contrasted by the reduced production of NO. Thus, mitochondria nitrosative-induced stress was just observed in young microglia and by the Bf highest level. Actually mitochondria has been pointed as a target of BIND ([@B12]) and mitochondrial depolarization and impairment of the respiratory chain previously reported in UCB-treated immature neurons ([@B102]).

Originally, it was accepted that microglia activation resulted in two main phenotypes, a proinflammatory M1 subtype and an anti-inflammatory and reparative subtype M2, though more recent studies showed that M1 and M2 are not isolated phenomena ([@B80]) and that multiple microglia phenotypic markers may co-exist ([@B100]). Evidences show that microglia can switch phenotypes and differentially express gene signatures in response to a variety of insults, either using microglial cell lines or primary cultures from mice modeling amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) ([@B19]; [@B76]; [@B105]). Here, we demonstrate that Bf increases the expression of mRNA levels of MHCII, TNF-α, IL-1β, and IL-6 inflammatory mediators in 2DIV microglia, from which only IL-1β was found elevated in 16DIV cells. These findings point to a predominant switch of young microglia to a pro-inflammatory phenotype by Bf, while it only scarcely activated the aged cells. Reinforcing the pro-inflammatory stimulus of Bf, downregulation of IL-10, an anti-inflammatory cytokine playing a critical role in immunoregulation ([@B86]; [@B54]), was present in both cell aged types. In short, microglia may be primed by Bf during neonatal hyperbilirubinemia leading to neurodevelopmental critical outcomes and increased susceptibilities to cognitive deficits by a secondary inflammatory insult in later life ([@B51]; [@B70]). To the best of our knowledge, this the first study showing that immature/neonatal microglia have an increased vulnerability to the pro-inflammatory effects of elevated concentrations of Bf. The slow response of the 16DIV maturated microglia to Bf immunostimulation may be associated to an acquired senescent-like phenotype ([@B18]) that was later demonstrated to be irresponsive to Aβ insult ([@B19]). Interestingly, as here reported, elevation of IL-1β was produced in 2DIV and 16DIV microglia upon Aβ incubation. Besides its role as a proinflammatory cytokine, IL-1β also belongs to the senescent-associated secretory phenotype (SASP) proteins ([@B69]). Thus, we hypothesize that the increased IL-1β mRNA levels in long maturated cells exposed to Bf may derive from the cell ageing, instead of being exclusively linked to a pro-inflammatory state. Up-regulation of arginase 1, mainly associated with the resolution of damage and associated with a neuroprotective profile ([@B26]) was similarly observed in cells cultured for short or long time after Bf treatment. Indeed, compensatory immune-inflammatory responses to UCB have been proposed in patients with bilirubin encephalopathy, where certain bioactive proteins, including defensins (e.g. α- defensin 1, DEFA1) and/or alarmins (e.g. C−reactive protein, S100A7 or S100A9) were differentially up/-down-regulated in extracellular vesicles isolated from the cerebrospinal fluid of those patients ([@B97]). Nevertheless, arginase 1 was also shown to support the inflammatory state in some studies ([@B1]) and to be upregulated by LPS in others ([@B116]). To additionally refer that upregulation of arginase 1 in both 2DIV and 16DIV microglia was observed upon Aβ incubation, as well ([@B19]).

Considering the key roles of microglia in neurogenesis and developmental synaptic pruning, as well as their trophic support ([@B28]), the early-life induced inflammation by Bf may have immediate and lasting consequences. Despite knowledge about miRNAs in neuroinflammation ([@B56]), little is known on their role in microglia inflammatory responses and mediated pathologies, though their dysregulation has been associated to perinatal brain injury ([@B25]). To date, no study has explored if and how inflamma-miRs are dysregulated in microglia activated by bilirubin, and whether the signature differs according to cell maturation. We assessed the expression of a set of inflamma-miRs recognized as mediators of the immunoregulatory microglial functions ([@B40]; [@B105]), namely miR-155, miR-146a, miR-125b, miR-124, and miR-21. Validating the Bf-immunostimulant effect on young microglia pro-inflammatory state, all miRNAs were found upregulated except miR-124 that mitigates microglia-induced neuroinflammation ([@B115]). From these miR-155 was shown to induce a pro-inflammatory response and to be early upregulated in the triple transgenic AD mouse model, while miR-124 acts as a negative regulator ([@B77]; [@B45]; [@B49]). Attesting the heterogeneity of activated microglia phenotypes by Bf in 2DIV cells, the overexpression of miR-21 and miR-146a shows that microglia may also induce the production of these inflammatory regulators ([@B110]) subsequently to Bf-induced microglial immunostimulation and upregulation of miR-155. Another important fine tuner of inflammation is miR-125b related to microglia activation in ALS ([@B72]). As a curiosity, in obstructive jaundice, miR-21 and miR-125b, among others, were found upregulated in the mouse liver ([@B55]) and the later associated with increased tau hyperphosphorylation ([@B4]; [@B117]). Again, exposure to bilirubin early in life in newborn rats was suggested to promote AD-like pathological changes later in life, including tau protein hyperphosphorylation, Aβ production and spatial learning and memory injuries ([@B22]), pointing to the significance of microglial priming in jaundiced infants during the neonatal period.

In contrast with the early activation of cortical microglia by Bf concentrations of 50 nM and 100 nM, decrease of miR-155, miR-146a, and miR-124, the three miRNAs most recognized as being involved in microglia inflammatory responses ([@B96]), in the aged cells highlight either a senescence-like cell behaviour and irresponsiveness to Bf stimulus, or alternatively an adaptive response to counteract the inflammatory stimulus ([@B99]; [@B18]; [@B72]; [@B19]).

In conclusion, this study adds to our understanding on how Bf can affect microglia dynamic properties, and support the vulnerability of the young cells, which turn overactivated even at moderated levels of Bf, as schematically represented in [**Figure 8**](#f8){ref-type="fig"}. The susceptibility of newborns and their immature nerve cells to BIND, together with the deregulation of microglial immune response by Bf with early and ensuing impacts in degenerative processes, suggest immunomodulation as a promising therapeutic strategy in neonates in risk for bilirubin encephalopathy and critical outcomes.

![Schematic representation of microglia response to free bilirubin (Bf), considering young and aged cultured cells. Microglial cells were treated at 2 (young) and 16 days-in-vitro (DIV) (aged) with 50 nM and 100 nM Bf for 24 h. Results show that short-cultured 2DIV microglia are more reactive to Bf than the long-cultured 16DIV cells. In young cells, both Bf concentrations favour Iba-1 amoeboid microglia and cause \~1.5-fold increase in CD11b-positive cells over aged microglia. Low levels of CX3CR1 and increased values of the alarmin HMGB1 in Bf-treated young cells, not exhibited by the aged cells, reinforce their proneness to Bf stimulation, a finding also reproduced by GLT-1 upregulation. Bf-induced mitochondrial-nitrosative stress (increased levels of either iNOS and NO) is again more notorious in 2DIV cells. These young microglia reveal to be unique in overexpressing inflammatory-associated markers upon Bf interaction (MHCII/TNF-α/IL1β/IL-6), apart arginase 1 (Arg1) and IL-1β that also increase in aged cells. The immunostimulant effect of Bf in the neonatal-like microglia and their increased reactivity to the injury is translated in the elevation of most of the inflammatory-associated miRNAs in 2DIV cells (miR-155/-125b/-21/-146a), while a depressed signature is found in the aged microglia. However, a common finding in the differently aged microglia by Bf interaction was the reduction of the "calming" IL-10 and miR-124 mediators in both, thus indicating the presence of shared immune responses. In sum, immune activation by Bf is more robust in early-life microglia and may increasingly impact on neonatal illness by hyperbilirubinemia, thus requiring immunoregulatory approaches to prevent clinical deterioration and related neurodevelopmental disabilities.](fphar-11-01012-g008){#f8}
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